Acceleron commences ACE-536 phase 2 research in beta-thalassemia Acceleron Pharma.

Acceleron commences ACE-536 phase 2 research in beta-thalassemia Acceleron Pharma, Inc male erections ., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a stage 2 study of it is novel today, investigational proteins therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder leading to chronic and life-threatening anemia and significant complications affecting the spleen, liver and heart.